The phase I/II CodeBreaK-100 trial (NCT03600883) investigating the clinically most advanced KRAS(G12C) inhibitor AMG-510 (international nonproprietary name (INN) sotorasib) reported a confirmed objective response rate (ORR) of ~32% and a disease control rate (DCR) of ~88% among lung cancer patients for the phase I trial part. This evidence concerns the gene KRAS and lung carcinoma.